Cybrid™ is a revolutionary live tumor ex vivo platform that offers biopharma companies the ability to characterize response to oncology immunotherapies rapidly and reliably.
Maintain tumor integrity, improve translatability
The Cybrid™ platform generates live tumor fragments (LTFs)™ directly from a tumor. The process conserves the native tumor microenvironment (TME) and architecture—including fully intact immune and support cells/structures, allowing for improved translatability and de-risking of drug development.
Get rapid results
In as little as 2 weeks of the study start date, we can offer results of the impact of your investigational agent on a tumor and its immune cells.
Experience easy access
A cloud-based portal, CybridView™ offers frictionless access to results and data from studies run through the Cybrid™ platform.
A breadth of outputs available across the development continuum
With Cybrid™ we can offer support at every stage of development with a range of critical outputs. These include:
- Secretome profiling
- Cellular markers via flow cytometry
- Transcriptome analysis
- Advanced 3D imaging
Download our Biopharma Services Overview below to learn how we can help accelerate your oncology immunotherapy development process.
